Radeviča steps down as President of LAA following a failed Olympic doping retest

To optimise for archiving, the original image and related documents associated with this article have been removed.

Former European long jump Champion Ineta Radeviča has decided to step down from her position as President of the Latvian Athletics Association after being tested positive for the steroid oxandrolone in a retest of her sample from the 2012 Olympics.

Radeviča finished fourth at the 2012 Olympics, missing the bronze medal by one centimeter. She is the fifth woman from that Olympic competition to face doping accusations. 3 athletes have been disqualified since the International Olympic Committee began retesting samples with modern methods.

The Latvian athlete retired from competition after the 2012 Olympics, and served as President of the LAA since 2017. Radeviča nevertheless insisted that she has not consumed doping wittingly, but did not go as far as to contradict the results of the test. 

Radeviča commented, ‘"Taking into account the present situation, I have decided to step down as president of the Latvian Athletics Association so that the started projects are finished and the federation is not put to risk”

You may also like

View All

Dallas judge prohibits NCAA and SEC from banning 41 athletes from returning to college sport for one more season

A Dallas judge has prohibited the National Collegiate Athletic Association and the Southeastern Conference from banning a number of athletes, 3 of which are part of NFL rosters, from returning to college sport for one more season 

Read More

Abuse victims receive over $3 million from Australian Institute of Sport

The Australian Institute of Sport has collectively paid over $3 million to over 225 athletes who experienced abuse at Australia’s elite sports training centre

Read More

Sport Resolutions’ 2025/26 Annual Report is ready to view

Sport Resolutions’ 2025/26 Annual Report is now live, providing a transparent, comprehensive summary of Sport Resolutions’ activity and profile across the last financial year (1 April 2025 – 31 March 2026), including some of our most notable concluded national and international cases and their outcomes

Read More